This pdf is shared by Creative Peptides.

1. Urotensin Related Peptides
Urotensin-II (U-II) is the strongest vasopressin ligand known. Because the U-II
system is involved in many biological systems, such as the cardiovascular
system, nervous system, endocrine system, and kidney system, it is a
promising target for the development of new drugs. Human Urotensin Ⅱ (hU-
Ⅱ) is a polypeptide composed of 11 amino acids. The primary structure of
Glu-Thr-Pro-Asp-cyclo [Cys-Phe-Trp-Lys-Tyr-Cys]-Val, is the strongest
vasoconstrictor peptide known so far. Its C-terminal highly conserved
hexapeptide structure Cys-Phe-Trp-Lys-Tyr-Cys is very similar to SST and
OCT. U-II plays a vasoactive role by binding to its specific receptor GPR14. It
has been found that SST and OCT can also compete to bind to the GPR14
receptor at high concentration and inhibit the vasoconstrictive activity of U-II.
Mode of Action
U-II plays a vasoactive role by binding to its specific orphan G-protein coupling
receptor GPR-14. The vasoactive effect of U-II is race-specific and
disease-specific. With the further study of U-II, it is found that U-II not only has
vascular activity but also has the effect of promoting mitosis and fibrosis. It has
been found that the expression of U-II is increased in plasma of patients with
liver cirrhosis, but its role in the occurrence and development of chronic liver
disease and portal hypertension. The mechanism is not yet clear.
Function
U-II has different effects on different tissues. It can cause a contraction in
blood vessels. In rat pancreas, U-II inhibits insulin secretion. It also affects the
kidneys, including sodium transport, lipid, and glucose metabolism, and
natriuretic action. It is associated with cardiac fibrosis and hypertrophy, heart
failure, renal insufficiency, and diabetes. The increased expression of U-II and
its receptor UT in the cirrhotic portal vein is closely related to the severity of the
disease and complications such as ascetic fluid. However, the specific
mechanism of U-II/UT system in the occurrence and development of cirrhotic
portal vein disease is not clear. The application of U-II receptor antagonist can
improve the hemodynamic disorder of portal hypertension and prevent hepatic

2. fibrosis, suggesting that U-II receptor antagonist may be an important tool for
the prevention and treatment of cirrhotic portal hypertension. The role in
cirrhotic portal hypertension can provide a new idea for the treatment of
cirrhotic portal hypertension.
References:
1. Merlino, F., Billard, É., Yousif, A. M., Di Maro, S., Brancaccio, D., Abate,
L., ... & Marinelli, L. (2019). Functional Selectivity Revealed by N-Methylation
Scanning of Human Urotensin II and Related Peptides. Journal of medicinal
chemistry, 62(3), 1455-1467.
2. Billard, É., Iddir, M., Nassour, H., Lee‐Gosselin, L., Poujol de Molliens, M.,
& Chatenet, D. (2019). New directions for urotensin II receptor ligands. Peptide
Science, 111(1), e24056.
Browse products name by alphabetical order:
ALLOU
Cat. # Product Name Price
U03002 Urotensin II-Related Peptide (human, mouse, rat) Inquir
U03004 Urotensin II, rat, [pGlu110] - Prepro - Urotensin II (110 - 123), rat Inquir
U03003 Urotensin II, human Inquir
U03006 Urotensin II , goby Inquir
U03007 Urotensin II (Frog) Inquir
U03005 Urotensin I Inquir
U03014 Urotensin II-Related Peptide (human, mouse, rat) trifluoroacetate salt Inquir
U03013 Urotensin II , human Inquir
U03012 Urotensin II , goby Inquir
U03011 Urotensin I Inquir
U03010 Orn8, Urotensin II, human Inquir

3. U03009 (Pyr1)-Urotensin II (rat) Inquir
U03008 (Pen5)-Urotensin II (4-11) (human) trifluoroacetate salt Inquir
U03001 (Pyr-110)-Prepro-Urotensin II (110-123) (rat) Inquir